Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001213900-25-031593
Filing Date
2025-04-14
Accepted
2025-04-14 16:30:35
Documents
15
Period of Report
2024-03-13
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 1 TO FORM 8-K ea0237290-8ka1_unicyc.htm   iXBRL 8-K/A 56270
2 FORM OF AMENDED AND RESTATED TRANCHE B WARRANT ea023729001ex4-2_unicyc.htm EX-4.2 60950
3 FORM OF AMENDED AND RESTATED TRANCHE C WARRANT ea023729001ex4-3_unicyc.htm EX-4.3 62286
  Complete submission text file 0001213900-25-031593.txt   397219

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE uncy-20240313.xsd EX-101.SCH 3017
5 XBRL LABEL FILE uncy-20240313_lab.xml EX-101.LAB 34239
6 XBRL PRESENTATION FILE uncy-20240313_pre.xml EX-101.PRE 22360
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0237290-8ka1_unicyc_htm.xml XML 4545
Mailing Address 4300 EL CAMINO REAL, SUITE 210 LOS ALTOS CA 94022
Business Address 4300 EL CAMINO REAL, SUITE 210 LOS ALTOS CA 94022 650-384-0642
Unicycive Therapeutics, Inc. (Filer) CIK: 0001766140 (see all company filings)

EIN.: 813638692 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-40582 | Film No.: 25836389
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)